Welcome! This is the NEW free version of the SciBITES Pharma News Engine from SciBite. By using this site you to accept our Terms & Conditions which the use of cookies to enhance your user experience.

The CD40/CD40L system: a new therapeutic target for disease.

Recieved:01-Jun-2013 00:00:00

Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Zhang, B; Wu, T; Chen, M; Zhou, Y; Yi, D; Guo, R

The role of CD40/CD40 ligand (CD40L) interactions in atherothrombosis, in the response of the immune system to pathogens and in thrombosis is now widely accepted. A role for CD40-CD40L interactions has been identified in atherosclerosis (AS), and such interactions are known to destabilize atherosclerotic plaques by inducing the expression of cytokines, chemokines, growth factors, matrix metalloproteinases and pro-coagulant factors. CD40/CD40L interactions have also been implicated in immune system disorders. Recent studies have suggested that CD40/CD40L interactions regulate oxidative stress and affect various signaling pathways in both the immunological and the cardiovascular systems. Here, we discuss the current drugs that target the CD40/CD40L system, as understanding the roles and regulations of CD40/CD40L-mediated signal pathways by these drugs could facilitate the development of therapeutics that target diverse diseases. Copyright © 2013 Elsevier B.V. All rights reserved.

Major Topics:
CD40 ligand    CD40 molecule, TNF receptor superfamily member 5   
Growth    Virulence    ligands    target    Cytokinesis    Signal Transduction    Oxidative Stress   
matrix metalloproteinase    cytokine    chemokine   
immune system disorder    Thrombosis   
immune system dysfunction    Atherosclerosis    Thrombosis    Atherosclerotic Plaque   

Click on any component of the trees below to see articles for any topic that is a member of that branch.